AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

EG30 for the treatment of Alzheimer's disease (Ramot)

Summary

EG-30: clinical phase drug for AMD and Glaucoma

EG-30 – the highlights:

· Excellent safety profile in healthy volunteers and glaucoma patients
• Low systemic exposure
• No increase in IOP in glaucoma patients treated with EG-30 for 16days (eye drops)
· Extensive safety and efficacy preclinical package:
• EG-30 inhibit the formation of amyloid beta oligomers and serve as a cytoprotectant agent
• Efficacy in dry AMD and glaucoma animal models
• Safety and toxicology including 6 months toxicology studies in rabbits and monkeys
· An FDA approved development path allowing a single confirmatory study for FDA approval of EG-30 for both glaucoma and dry AMD
· New derivatives for Alzheimer treatment

ID No.

10-2011-274

Country/Region

Israel

For more information, please click Here